Last reviewed · How we verify
CBL-514
CBL-514 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling.
CBL-514 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling. Used for FGFR-driven solid tumors (specific indications in phase 3 development).
At a glance
| Generic name | CBL-514 |
|---|---|
| Sponsor | Caliway Biopharmaceuticals Co., Ltd. |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CBL-514 targets FGFR pathways that are dysregulated in various cancers and fibrotic diseases. By inhibiting FGFR signaling, the drug aims to suppress tumor growth and reduce pathological fibrosis. The selective nature of the inhibitor is designed to minimize off-target effects while maintaining efficacy against FGFR-dependent malignancies.
Approved indications
- FGFR-driven solid tumors (specific indications in phase 3 development)
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat (PHASE3)
- A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas (PHASE2)
- A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat. (PHASE2)
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) (PHASE2)
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (PHASE2)
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1) (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBL-514 CI brief — competitive landscape report
- CBL-514 updates RSS · CI watch RSS
- Caliway Biopharmaceuticals Co., Ltd. portfolio CI